Skip to main content

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

Recruiting · NCT07001280

Conditions: Hereditary Angioedemas

At a glance

Research payments reported, 2025
$44,480
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
200

About the trial

Sponsor
CSL Behring
Tested
No intervention (other)
Dates
Started 2025-07-21; completion 2030-08-31
Results posted
Not yet

This is a multinational, multicenter, prospective, observational cohort study of patients with HAE in the real-world setting. The study will include patients newly initiating garadacimab in routine clinical practice. Each participant will be followed for 48 months after index date (date of the first administration of garadacimab). Patient data will be collected from the HAE eDiary, patient medical records (MRs) and/or during a routine clinical visit and will be entered into the electronic case report form (eCRF) via an electronic data capture (EDC) system. Data pertaining to HAE attacks, prior HAE treatments, retrospective focused safety data collection, and healthcare resource utilizatio…

From ClinicalTrials.gov, last updated 2026-06-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Csl Behring reported $44,480 in research payments for this study in 2025 (6 payments).

Products named: Andembry

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Washington University $26,400
  • $10,580
  • Johns Hopkins Institute for Assured Autonomy (iaa) Clinical Research $7,500

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.